We are live on ! Find out more

Candel Therapeutics

CADL

Market cap $662M

8.65 USD

-0.02

0.23%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

8.51

-0.14

1.62%

1 day

-0.23%

5 days

3.84%

1 month

-20.5%

3 months

-7.98%

6 months

39.97%

Year to date

59.01%

1 year

57.56%

5 years

-22.97%

10 years

23.57%

About: Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Employees: 55

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 26.3%

Neutral 73.7%

Negative 0%

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

Candel Therapeutics to Present at November Investor Conferences

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026.

Candel Therapeutics to Present at November Investor Conferences

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel's legal and compliance functions, including corporate governance, and report to Candel's President and Chief Executive Officer.

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8, 2026 in Phoenix, Arizona.

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company's common stock, with a per share exercise price of $10.44.

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate response to ICI. The trial demonstrated a median overall survival (mOS) of 24.5 months in the evaluable population, substantially exceeding historical benchmarks for standard-of-care docetaxel chemotherapy in this patient population.

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial (NCT07332000) in patients with intermediate-risk localized prostate cancer. These data, together with histologic and clinical data from the intermediate-risk prostate cancer subgroup of the PrTK03 phase 3 trial (NCT01436968) (635 patients, 85% of the intention-to-treat population), are expected to be presented at a future scientific meeting. Intermediate-risk prostate cancer represents the largest group of patients with localized disease treated with curative-intent external beam radiation therapy (EBRT), accounting for approximately 65,000 patients annually in the United States. Despite radiotherapy, disease recurrence, local and metastatic progression, and the need for salvage anti-cancer therapies that can be associated with substantial toxicity and impaired quality of life remain important unmet needs. This underscores the need for new treatments designed to enhance local tumor control and reduce the risk of disease progression.

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026.

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing disease recurrence risk by 30% and supporting a BLA filing in Q4 2026. Upcoming catalysts include phase 3 biomarker data at ASTRO 2026 and advancing aglatimagene in metastatic NSCLC with the AURORA trial.

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

Zacks Investment Research

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

See News Rankings

Price charts implemented using Lightweight Charts™